BioCentury
ARTICLE | Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 1, 2020 11:29 PM UTC
Updated on Apr 1, 2020 at 11:56 PM UTC

Backed by preclinical and clinical data that support blocking complement to mitigate coronavirus-mediated respiratory distress, InflaRx has begun a clinical study of its own complement inhibitor to treat COVID-19 patients with severe pneumonia.

InflaRx N.V. (NASDAQ:IFRX) announced after market close Tuesday that it has dosed the first patient in a randomized clinical trial of IFX-1, a mAb against C5a, to treat severe pneumonia due to SARS-CoV-2 infection...

BCIQ Company Profiles

InflaRx N.V.

BCIQ Target Profiles

Complement 5a (C5a)